Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice.

Expert review of anti-infective therapy·2021
Same author

Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives.

Expert review of anticancer therapy·2020
Same author

Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.

Expert opinion on pharmacotherapy·2017
Same author

Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146(5):1222-1230 e1222.

Expert opinion on pharmacotherapy·2014
Same author

Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire.

Expert review of pharmacoeconomics & outcomes research·2014
Same author

Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis.

Journal of comparative effectiveness research·2013

Related Experiment Video

Updated: Jun 9, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Daclizumab: a potential asthma therapy?

Sabina A Antoniu1

  • 1Gr T Popa University of Medicine and Pharmacy Iaşi, Department of Medicine II -Pulmonary Disease, Pulmonary University Hospital, 30 Dr I Cihac Str, 700115 Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro

Recent Patents on Inflammation & Allergy Drug Discovery
|September 1, 2010
PubMed
Summary

Interleukin-2 (IL-2) drives asthma inflammation via Th2 cells. Blocking the IL-2 receptor with daclizumab may offer a novel therapy for asthma, complementing existing treatments.

Related Experiment Videos

Last Updated: Jun 9, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Asthma involves CD4+ (Th2) cell-mediated inflammation, driven by IL-2, leading to eosinophilia, IgE, and mucus.
  • Current asthma therapies like corticosteroids and leukotriene modifiers have limitations in efficacy.
  • The IL-2 pathway's central role in asthma pathogenesis suggests it as a therapeutic target.

Purpose of the Study:

  • To review the pathogenic role of IL-2 in asthma.
  • To evaluate the therapeutic potential of daclizumab, an IL-2 receptor blocker, for asthma.
  • To examine patents related to daclizumab in asthma treatment.

Main Methods:

  • Literature review of IL-2's role in asthma.
  • Analysis of daclizumab's mechanism of action as an IL-2R antagonist.
  • Review of existing patent landscape for daclizumab and asthma.

Main Results:

  • IL-2 is a key initiator and sustainer of Th2-driven airway inflammation in asthma.
  • Daclizumab, by blocking IL-2 signaling, presents a promising strategy for asthma control.
  • The patent landscape indicates developing interest in IL-2 pathway inhibition for respiratory diseases.

Conclusions:

  • Targeting the IL-2 pathway, specifically with IL-2R blockers like daclizumab, holds significant therapeutic potential for asthma.
  • Daclizumab may offer an alternative or adjunctive treatment for patients with inadequately controlled asthma.
  • Further clinical investigation is warranted to establish daclizumab's efficacy and safety in asthma management.